PL2231707T3 - Przeciwciała przeciwko MIF - Google Patents

Przeciwciała przeciwko MIF

Info

Publication number: PL2231707T3
Authority: PL; Poland
Prior art keywords: mif antibodies; anti mif; antibodies; mif
Prior art date: 2008-01-04

Application number

PL08869976T

Other languages

English (en)

Inventor

Randolf Kerschbaumer

Friedrich Scheiflinger

Manfred Rieger

Michael Thiele

C Geert Mudde

Juergen Muellberg

Rene Hoet

Original Assignee

Baxalta Inc

Baxalta GmbH

Dyax Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-04

Filing date

2008-12-30

Publication date

2015-05-29

2008-12-30 Application filed by Baxalta Inc, Baxalta GmbH, Dyax Corp filed Critical Baxalta Inc

2015-05-29 Publication of PL2231707T3 publication Critical patent/PL2231707T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)

PL08869976T 2008-01-04 2008-12-30 Przeciwciała przeciwko MIF PL2231707T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US1898808P	2008-01-04	2008-01-04
US9468508P	2008-09-05	2008-09-05
EP08869976.4A EP2231707B1 (en)	2008-01-04	2008-12-30	Anti mif antibodies
PCT/EP2008/011146 WO2009086920A1 (en)	2008-01-04	2008-12-30	Anti mif antibodies

Publications (1)

Publication Number	Publication Date
PL2231707T3 true PL2231707T3 (pl)	2015-05-29

Family

ID=40535633

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL08869976T PL2231707T3 (pl)	2008-01-04	2008-12-30	Przeciwciała przeciwko MIF
PL16183733T PL3118223T3 (pl)	2008-01-04	2008-12-30	Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL16183733T PL3118223T3 (pl)	2008-01-04	2008-12-30	Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych

Country Status (22)

Country	Link
US (3)	US20090220521A1 (pl)
EP (4)	EP3118223B8 (pl)
JP (1)	JP5502752B2 (pl)
KR (2)	KR101654678B1 (pl)
CN (2)	CN103724430B (pl)
AU (1)	AU2008346517B2 (pl)
BR (1)	BRPI0821682A2 (pl)
CA (1)	CA2711029A1 (pl)
CY (1)	CY1117302T1 (pl)
DK (1)	DK2231707T3 (pl)
ES (3)	ES2623653T3 (pl)
HR (1)	HRP20150224T1 (pl)
IL (1)	IL206715A (pl)
MX (1)	MX2010007406A (pl)
NZ (3)	NZ611117A (pl)
PL (2)	PL2231707T3 (pl)
PT (1)	PT2231707E (pl)
RS (1)	RS53906B1 (pl)
RU (2)	RU2509777C2 (pl)
SI (1)	SI2231707T1 (pl)
WO (1)	WO2009086920A1 (pl)
ZA (1)	ZA201004973B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2231707T3 (pl) *	2008-01-04	2015-05-29	Baxalta Inc	Przeciwciała przeciwko MIF
WO2013010955A1 (en)	2011-07-15	2013-01-24	Morphosys Ag	Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
JP2014530361A (ja) *	2011-10-07	2014-11-17	バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒＨｅａｌｔｈｃａｒｅＳＡ	Ｃｈｏ−ｍｉｆ遺伝子およびタンパク質の特性評価およびその使用
AU2012320597C1 (en)	2011-10-07	2015-10-15	Baxalta GmbH	oxMIF as a diagnostic marker
AU2013203957B9 (en) *	2012-04-16	2015-10-15	Baxalta GmbH	Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
AU2013202693B2 (en) *	2012-04-16	2015-01-22	Baxalta GmbH	Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
CN105452867A (zh)	2012-07-10	2016-03-30	巴克斯特保健股份有限公司	抗-mif的免疫组织化学
CA2893249A1 (en) *	2012-12-07	2014-06-12	Baxter International Inc.	Anti-mif antibody cell migration assay
AU2015206178A1 (en) *	2014-01-03	2016-07-07	Baxalta GmbH	Anti-MIF immunohistochemistry
US10626166B2 (en)	2014-08-22	2020-04-21	Baxalta Incorporated	Detection of CHO-MIF contaminations
EP3277718B1 (en)	2015-03-31	2021-03-24	Baxalta GmbH	Dosage regimen for anti-mif antibodies
EP3298039A1 (en)	2015-05-18	2018-03-28	Baxalta GmbH	Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
US11098113B2 (en)	2016-09-15	2021-08-24	Vib Vzw	Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN109868311B (zh) *	2017-12-01	2023-10-20	上海市精神卫生中心	Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用
KR20210018800A (ko)	2018-06-07	2021-02-18	온코원 리서치 앤드 디벨롭먼트 게엠베하	암 치료를 위한 항-oxMIF/항-CD3 항체
EP3757252B1 (en)	2019-06-28	2022-03-30	Walter Ag	A coated cutting tool
JP2023504620A (ja)	2019-12-06	2023-02-06	オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
AU2021354917A1 (en) *	2020-10-02	2023-05-18	Oncoone Research & Development Gmbh	IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
JP2024505963A (ja) *	2021-02-03	2024-02-08	オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	抗ｏｘＭＩＦ放射性免疫コンジュゲート
ES3038265T3 (en)	2021-09-03	2025-10-10	Oncoone Res & Development Gmbh	Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
US20250213710A1 (en) *	2022-01-10	2025-07-03	Phenomic Ai	Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same
CN114573693A (zh) *	2022-04-25	2022-06-03	中国人民解放军陆军军医大学	一种听觉发育中免疫调节分子mif抗体制备方法
CN115814069B (zh) *	2022-10-31	2023-07-21	四川大学华西医院	Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途
JP2026507847A (ja)	2023-03-03	2026-03-06	オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	過剰増殖性障害のプレターゲティングのための二重特異性抗腫瘍抗原／抗ｈｓｇ抗体の改善
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025171411A1 (en) *	2024-02-09	2025-08-14	Herophilus, Inc.	Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6774227B1 (en) *	1993-05-17	2004-08-10	Cytokine Pharmasciences, Inc.	Therapeutic uses of factors which inhibit or neutralize MIF activity
US6030615A (en) *	1993-05-17	2000-02-29	The Picower Institute For Medical Research	Combination method for treating diseases caused by cytokine-mediated toxicity
JPH0977799A (ja) *	1995-09-13	1997-03-25	Sapporo Immuno Diagnostic Lab:Kk	ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
DK1156823T3 (da) *	1999-02-12	2009-01-19	Scripps Research Inst	Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
AU2001238677A1 (en) *	2000-02-28	2001-09-12	Idec Pharmaceuticals Corporation	Method for preparing anti-mif antibodies
AR045563A1 (es) *	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
CN100457895C (zh) *	2006-05-24	2009-02-04	中国科学院生物物理研究所	鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
PL2231707T3 (pl) *	2008-01-04	2015-05-29	Baxalta Inc	Przeciwciała przeciwko MIF

2008
- 2008-12-30 PL PL08869976T patent/PL2231707T3/pl unknown
- 2008-12-30 MX MX2010007406A patent/MX2010007406A/es active IP Right Grant
- 2008-12-30 NZ NZ611117A patent/NZ611117A/en not_active IP Right Cessation
- 2008-12-30 ES ES14163839.5T patent/ES2623653T3/es active Active
- 2008-12-30 US US12/346,309 patent/US20090220521A1/en not_active Abandoned
- 2008-12-30 HR HRP20150224TT patent/HRP20150224T1/hr unknown
- 2008-12-30 ES ES08869976.4T patent/ES2531629T3/es active Active
- 2008-12-30 RU RU2010132647/10A patent/RU2509777C2/ru active
- 2008-12-30 RS RS20150197A patent/RS53906B1/sr unknown
- 2008-12-30 PT PT08869976T patent/PT2231707E/pt unknown
- 2008-12-30 EP EP16183733.1A patent/EP3118223B8/en active Active
- 2008-12-30 EP EP20120189220 patent/EP2548890A1/en not_active Withdrawn
- 2008-12-30 CN CN201410037650.3A patent/CN103724430B/zh not_active Expired - Fee Related
- 2008-12-30 NZ NZ586600A patent/NZ586600A/en not_active IP Right Cessation
- 2008-12-30 EP EP14163839.5A patent/EP2754671B1/en active Active
- 2008-12-30 CA CA2711029A patent/CA2711029A1/en not_active Abandoned
- 2008-12-30 JP JP2010541032A patent/JP5502752B2/ja not_active Expired - Fee Related
- 2008-12-30 AU AU2008346517A patent/AU2008346517B2/en not_active Ceased
- 2008-12-30 DK DK08869976.4T patent/DK2231707T3/en active
- 2008-12-30 SI SI200831400T patent/SI2231707T1/sl unknown
- 2008-12-30 EP EP08869976.4A patent/EP2231707B1/en active Active
- 2008-12-30 KR KR1020107017306A patent/KR101654678B1/ko active Active
- 2008-12-30 KR KR1020167023984A patent/KR20160105943A/ko not_active Ceased
- 2008-12-30 WO PCT/EP2008/011146 patent/WO2009086920A1/en not_active Ceased
- 2008-12-30 CN CN200880127872.7A patent/CN101983207B/zh not_active Expired - Fee Related
- 2008-12-30 PL PL16183733T patent/PL3118223T3/pl unknown
- 2008-12-30 NZ NZ596409A patent/NZ596409A/xx not_active IP Right Cessation
- 2008-12-30 ES ES16183733T patent/ES2791333T3/es active Active
- 2008-12-30 BR BRPI0821682-7A patent/BRPI0821682A2/pt not_active IP Right Cessation
2010
- 2010-04-26 US US12/767,635 patent/US8668909B2/en active Active
- 2010-06-30 IL IL206715A patent/IL206715A/en active IP Right Grant
- 2010-07-14 ZA ZA2010/04973A patent/ZA201004973B/en unknown
2013
- 2013-12-03 RU RU2013153592/10A patent/RU2013153592A/ru not_active Application Discontinuation
2014
- 2014-01-17 US US14/157,967 patent/US20150023978A1/en not_active Abandoned
2015
- 2015-03-13 CY CY20151100250T patent/CY1117302T1/el unknown

Also Published As

Publication number	Publication date
MX2010007406A (es)	2010-10-05
EP3118223B1 (en)	2020-02-19
CY1117302T1 (el)	2017-04-26
HK1147762A1 (en)	2011-08-19
RU2010132647A (ru)	2012-02-10
EP2754671B1 (en)	2016-12-21
SI2231707T1 (sl)	2015-04-30
CN101983207A (zh)	2011-03-02
NZ586600A (en)	2012-05-25
RU2509777C2 (ru)	2014-03-20
DK2231707T3 (en)	2015-03-02
EP3118223A1 (en)	2017-01-18
EP2548890A1 (en)	2013-01-23
BRPI0821682A2 (pt)	2015-06-16
ES2531629T3 (es)	2015-03-18
HRP20150224T1 (xx)	2015-06-05
JP5502752B2 (ja)	2014-05-28
EP2231707B1 (en)	2014-12-24
AU2008346517A1 (en)	2009-07-16
US20100260768A1 (en)	2010-10-14
CA2711029A1 (en)	2009-07-16
NZ611117A (en)	2014-10-31
WO2009086920A1 (en)	2009-07-16
ES2623653T3 (es)	2017-07-11
PT2231707E (pt)	2015-03-25
KR20160105943A (ko)	2016-09-07
US20090220521A1 (en)	2009-09-03
RS53906B1 (sr)	2015-08-31
EP2754671A3 (en)	2015-07-08
NZ596409A (en)	2013-05-31
IL206715A (en)	2015-06-30
EP3118223B8 (en)	2020-04-15
ES2791333T3 (es)	2020-11-03
IL206715A0 (en)	2010-12-30
RU2013153592A (ru)	2015-06-10
KR101654678B1 (ko)	2016-09-08
EP2754671A2 (en)	2014-07-16
EP2231707A1 (en)	2010-09-29
US20150023978A1 (en)	2015-01-22
CN101983207B (zh)	2016-01-20
ZA201004973B (en)	2011-03-30
PL3118223T3 (pl)	2021-04-06
AU2008346517B2 (en)	2013-12-05
CN103724430B (zh)	2016-09-21
JP2011510616A (ja)	2011-04-07
CN103724430A (zh)	2014-04-16
US8668909B2 (en)	2014-03-11
KR20100102197A (ko)	2010-09-20

Publication	Publication Date	Title
ZA201004973B (en)	2011-03-30	Anti mif antibodies
GB0821100D0 (en)	2008-12-24	Antibodies
ZA201102119B (en)	2011-12-28	Improved antibody libraies
IL212701A0 (en)	2011-07-31	Improved anti-cd19 antibodies
PL2374883T3 (pl)	2017-05-31	Przeciwciało anty-CD4
GB0708002D0 (en)	2007-06-06	Antibodies
ZA201100300B (en)	2012-01-25	Anti-cd5 antibodies
IL212175A0 (en)	2011-06-30	Muc1* antibodies
EP2331579A4 (en)	2013-01-23	MONOCLONAL ANTIBODIES
IL210903A0 (en)	2011-04-28	Anit-il-12/il-23 antibodies
IL205607A0 (en)	2010-11-30	Axl antibodies
SI2262831T1 (sl)	2015-10-30	Protitelesa anti-properdina
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
IL201552A0 (en)	2010-05-31	Antibodies against il-25
GB0817891D0 (en)	2008-11-05	Antibodies against il-25
GB0718737D0 (en)	2007-11-07	Antibodies
GB0905972D0 (en)	2009-05-20	Antibodies against IL-17BR
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
EP2264071A4 (en)	2011-05-04	ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION
GB0806230D0 (en)	2008-05-14	Antibodies
GB0823562D0 (en)	2009-01-28	Antibodies
GB0819113D0 (en)	2008-11-26	An antibody
GB0817621D0 (en)	2008-11-05	Antibody